CytRx Corporation Company Profile (NASDAQ:CYTR)

About CytRx Corporation (NASDAQ:CYTR)

CytRx Corporation logoCytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYTR
  • CUSIP: N/A
  • Web: www.cytrx.com
Capitalization:
  • Market Cap: $69.93 million
  • Outstanding Shares: 165,710,000
Average Prices:
  • 50 Day Moving Avg: $0.56
  • 200 Day Moving Avg: $0.55
  • 52 Week Range: $0.36 - $1.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.03
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $100,000.00
  • Price / Sales: 699.30
  • Book Value: $0.13 per share
  • Price / Book: 3.38
Profitability:
  • EBIDTA: ($41,940,000.00)
  • Return on Equity: -222.67%
  • Return on Assets: -74.07%
Debt:
  • Debt-to-Equity Ratio: 0.82%
  • Current Ratio: 2.44%
  • Quick Ratio: 2.44%
Misc:
  • Average Volume: 5.77 million shs.
  • Beta: 2.55
  • Short Ratio: 2.28
 

Frequently Asked Questions for CytRx Corporation (NASDAQ:CYTR)

What is CytRx Corporation's stock symbol?

CytRx Corporation trades on the NASDAQ under the ticker symbol "CYTR."

How were CytRx Corporation's earnings last quarter?

CytRx Corporation (NASDAQ:CYTR) issued its earnings results on Wednesday, May, 10th. The company reported ($0.10) EPS for the quarter. View CytRx Corporation's Earnings History.

When will CytRx Corporation make its next earnings announcement?

CytRx Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for CytRx Corporation.

Where is CytRx Corporation's stock going? Where will CytRx Corporation's stock price be in 2017?

3 brokers have issued 1-year price targets for CytRx Corporation's shares. Their predictions range from $3.00 to $4.00. On average, they anticipate CytRx Corporation's share price to reach $3.50 in the next twelve months. View Analyst Ratings for CytRx Corporation.

Who are some of CytRx Corporation's key competitors?

Who are CytRx Corporation's key executives?

CytRx Corporation's management team includes the folowing people:

  • John Y Caloz, Chief Financial Officer
  • David J. Haen, Vice President - Business Development
  • Shanta Chawla M.D., Senior Executive Officer - Drug Development
  • Olivia C. Ware, Chief Commercial Officer
  • Steven A. Kriegsman, Chairman of the Board, President, Chief Executive Officer
  • Earl W. Brien M.D., Director
  • Joel Caldwell, Director
  • Louis J. Ignarro Ph.D., Independent Director

Who owns CytRx Corporation stock?

CytRx Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.17%), Goldman Sachs Group Inc. (0.42%), LMR Partners LLP (0.25%) and Northern Trust Corp (0.16%). View Institutional Ownership Trends for CytRx Corporation.

Who sold CytRx Corporation stock? Who is selling CytRx Corporation stock?

CytRx Corporation's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for CytRx Corporation.

Who bought CytRx Corporation stock? Who is buying CytRx Corporation stock?

CytRx Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Goldman Sachs Group Inc. and LMR Partners LLP. View Insider Buying and Selling for CytRx Corporation.

How do I buy CytRx Corporation stock?

Shares of CytRx Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytRx Corporation's stock price today?

One share of CytRx Corporation stock can currently be purchased for approximately $0.42.


MarketBeat Community Rating for CytRx Corporation (NASDAQ CYTR)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  297
MarketBeat's community ratings are surveys of what our community members think about CytRx Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CytRx Corporation (NASDAQ:CYTR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (729.38% upside)

Analysts' Ratings History for CytRx Corporation (NASDAQ:CYTR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/26/2017HC WainwrightReiterated RatingBuy$4.00HighView Rating Details
3/21/2017AegisReiterated RatingBuyMediumView Rating Details
11/14/2016FBR & CoSet Price TargetBuy$3.00N/AView Rating Details
7/15/2016Jefferies Group LLCReiterated RatingHold$2.50 -> $0.75N/AView Rating Details
7/12/2016S&P Equity ResearchLower Price Target$1.04 -> $0.75N/AView Rating Details
11/6/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$10.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for CytRx Corporation (NASDAQ:CYTR)
Earnings by Quarter for CytRx Corporation (NASDAQ:CYTR)
Earnings History by Quarter for CytRx Corporation (NASDAQ CYTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017N/AView Earnings Details
5/10/2017Q1 2017($0.10)ViewN/AView Earnings Details
7/29/2016Q2($0.19)($0.27)$0.10 millionViewN/AView Earnings Details
5/11/2016Q116($0.26)($0.19)ViewN/AView Earnings Details
11/3/2015Q315($0.24)($0.17)ViewN/AView Earnings Details
8/3/2015Q215($0.27)($0.25)ViewN/AView Earnings Details
5/1/2015Q115($0.21)($0.28)ViewN/AView Earnings Details
3/10/2015Q4 2014($0.27)($0.24)$0.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.25)($0.10)ViewN/AView Earnings Details
8/6/2014Q214($0.20)($0.28)ViewN/AView Earnings Details
3/5/2014($0.17)($0.25)$0.10 millionViewN/AView Earnings Details
10/29/2013Q313($0.22)($0.33)$0.20 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.19)($0.11)ViewN/AView Earnings Details
5/9/2013Q113($0.15)($0.23)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.20)($0.21)ViewN/AView Earnings Details
11/9/2012Q312$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytRx Corporation (NASDAQ:CYTR)
Current Year EPS Consensus Estimate: $-0.500 EPS
Next Year EPS Consensus Estimate: $-0.410 EPS

Dividends

Dividend History for CytRx Corporation (NASDAQ:CYTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CytRx Corporation (NASDAQ:CYTR)
Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 7.83%
Insider Trades by Quarter for CytRx Corporation (NASDAQ:CYTR)
Institutional Ownership by Quarter for CytRx Corporation (NASDAQ:CYTR)
Insider Trades by Quarter for CytRx Corporation (NASDAQ:CYTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/3/2013Scott Bradford Pattersonmajor shareholderBuy284,979$2.44$695,348.76View SEC Filing  
11/7/2013Scott Bradford PattersonMajor ShareholderBuy50,000$2.06$103,000.00View SEC Filing  
4/1/2013Scott Bradford PattersonMajor ShareholderBuy4,083$2.70$11,024.10View SEC Filing  
3/20/2013Scott Bradford PattersonMajor ShareholderBuy3,980$2.61$10,387.80View SEC Filing  
3/13/2013Scott Bradford PattersonMajor ShareholderBuy55,360$2.67$147,811.20View SEC Filing  
10/22/2012Scott Bradford PattersonMajor ShareholderBuy180,000$2.51$451,800.00View SEC Filing  
10/18/2012Scott Bradford PattersonMajor ShareholderBuy1,200,000$2.50$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CytRx Corporation (NASDAQ:CYTR)
Latest Headlines for CytRx Corporation (NASDAQ:CYTR)
Source:
DateHeadline
reuters.com logoBRIEF-CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split​ - Reuters
www.reuters.com - September 21 at 5:46 PM
prnewswire.com logoLeading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the ... - PR Newswire (press release)
www.prnewswire.com - September 21 at 5:46 PM
finance.yahoo.com logoLeading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the Proposed Reverse Stock Split
finance.yahoo.com - September 21 at 9:48 AM
prnewswire.com logoCytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting - PR Newswire (press release)
www.prnewswire.com - September 14 at 11:33 PM
reuters.com logoBRIEF-CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting
www.reuters.com - September 13 at 7:00 PM
finance.yahoo.com logoCytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting
finance.yahoo.com - September 13 at 7:00 PM
seekingalpha.com logoDerivative Action Seeks To Benefit Nominal Defendant CytRx Corporation
seekingalpha.com - September 7 at 5:52 PM
americanbankingnews.com logoCytRx Corporation (CYTR) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - September 3 at 3:58 PM
prnewswire.com logoCytRx Corporation Files Definitive Proxy Statement for Upcoming Special Meeting - PR Newswire (press release)
www.prnewswire.com - August 30 at 6:53 PM
finance.yahoo.com logoCytRx Corporation Files Definitive Proxy Statement for Upcoming Special Meeting
finance.yahoo.com - August 30 at 6:53 PM
streetinsider.com logoCytRx (CYTR) to Request Hearing After Failing to Regain Compliance with Nasdaq Minimum Bid Price Requirement
www.streetinsider.com - August 24 at 5:55 PM
finance.yahoo.com logoCytRx Corporation Announces Receipt of NASDAQ Listing Determination
finance.yahoo.com - August 24 at 5:55 PM
prnewswire.com logoCytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting - PR Newswire (press release)
www.prnewswire.com - August 22 at 11:25 PM
finance.yahoo.com logoCytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting
finance.yahoo.com - August 21 at 5:26 PM
finance.yahoo.com logoCytRx New Drug Development Agreement Brings Cash and Experience
finance.yahoo.com - August 10 at 7:01 PM
prnewswire.com logoCytRx Reports Second Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - August 3 at 7:08 PM
finance.yahoo.com logoCytRx Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 7:08 PM
finance.yahoo.com logoCytRx reports 2Q loss
finance.yahoo.com - August 3 at 7:08 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: CytRx Corporation and ImmunoGen
finance.yahoo.com - July 31 at 5:36 PM
rttnews.com logoDVAX Surges On FDA Panel Vote, CYTR On Watch, EC Approves New HCV Drugs
www.rttnews.com - July 31 at 2:58 AM
streetinsider.com logoCytRx (CYTR) and NantCell Enter Global Strategic License for Aldoxorubicin
www.streetinsider.com - July 29 at 5:47 AM
reuters.com logoBRIEF-Cytrx Corp announces Global Strategic License With Nantcell for Aldoxorubicin
www.reuters.com - July 29 at 5:47 AM
americanbankingnews.com logoCytRx Corporation (NASDAQ:CYTR) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - July 28 at 11:41 PM
prnewswire.com logoCytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated ... - PR Newswire (press release)
www.prnewswire.com - July 28 at 7:44 PM
finance.yahoo.com logoCytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic
finance.yahoo.com - July 28 at 7:44 PM
americanbankingnews.com logoShort Interest in CytRx Corporation (CYTR) Declines By 17.8%
www.americanbankingnews.com - July 15 at 7:06 AM
seekingalpha.com logoCytRx: SCLC Study Still Breathing?
seekingalpha.com - July 14 at 12:07 AM
americanbankingnews.com logoCytRx Corporation (NASDAQ:CYTR) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 13 at 9:32 AM
finance.yahoo.com logoPenny Stocks to Watch for June 2017 (CYTR, DELT)
finance.yahoo.com - June 30 at 5:50 PM
americanbankingnews.com logoCytRx Corporation (CYTR) Short Interest Update
www.americanbankingnews.com - June 28 at 7:09 AM
prnewswire.com logoCytRx Announces Reshaping of Clinical and Regulatory Executive Team - PR Newswire (press release)
www.prnewswire.com - June 14 at 5:36 PM
finance.yahoo.com logoCytRx Announces Reshaping of Clinical and Regulatory Executive Team
finance.yahoo.com - June 13 at 12:20 PM
americanbankingnews.com logoShort Interest in CytRx Co. (CYTR) Expands By 79.2%
www.americanbankingnews.com - June 11 at 7:16 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: CytRx and Hydrogenics Corporation
finance.yahoo.com - June 9 at 8:29 AM
finance.yahoo.com logoCytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas
finance.yahoo.com - June 8 at 10:06 AM
finance.yahoo.com logoGoodbye CytRx, Your Game is Over
finance.yahoo.com - June 5 at 4:42 PM
nasdaq.com logoWall Street Set to Open in Red Territory, Data in Focus
www.nasdaq.com - May 30 at 11:47 AM
americanbankingnews.com logoShort Interest in CytRx Co. (CYTR) Declines By 51.6%
www.americanbankingnews.com - May 27 at 7:06 AM
benzinga.com logoMost Notable Abstracts Released Ahead Of ASCO 2017 | Benzinga - Benzinga
www.benzinga.com - May 19 at 4:29 PM
finance.yahoo.com logoThe Most Notable Abstracts Released Ahead Of ASCO 2017
finance.yahoo.com - May 19 at 4:29 PM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx
finance.yahoo.com - May 19 at 8:22 AM
streetinsider.com logoB. Riley Financial (RILY) Announces $67M Acquisition of Wunderlich Securities
www.streetinsider.com - May 18 at 10:45 AM
finance.yahoo.com logoCytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 9:45 PM
americanbankingnews.com logoCytRx Co. (CYTR) Posts Earnings Results
www.americanbankingnews.com - May 11 at 6:54 PM
americanbankingnews.com logoCytRx Co. (CYTR) Sees Large Growth in Short Interest
www.americanbankingnews.com - May 11 at 7:20 AM
finance.yahoo.com logoCytRx Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 4:50 PM
finance.yahoo.com logoCytRx reports 1Q loss
finance.yahoo.com - May 10 at 4:50 PM
ft.com logoFake news infiltrates financial markets
www.ft.com - May 5 at 2:51 AM
streetinsider.com logoCytRx (CYTR) Announces Offering of Common Stock
www.streetinsider.com - April 29 at 10:18 PM
prnewswire.com logoCytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock - PR Newswire (press release)
www.prnewswire.com - April 29 at 5:17 PM

Social

Chart

CytRx Corporation (CYTR) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff